Infection Control Today

OCT 2018

ICT delivers to infection preventionists & their colleagues in the operating room, sterile processing/central sterile, environmental services & materials management, timely & relevant news, trends & information impacting the profession & the industry

Issue link: http://digital.infectioncontroltoday.com/i/1025165

Contents of this Issue

Navigation

Page 29 of 40

29 October 2018 ICT Deadly Pathogens are Great at Hide-n-Seek But SteraMist™ Always Finds Them The only EPA registered solution and equipment combination for hospital disinfecting that goes above, beyond, under and around to fnd them and reduce the spread of deadly pathogens. Easily Implement SteraMist™ Into Your Protocols Today! 800.525.1698 | tomimist.com body within the U.S. government with the authority and budget to develop a proactive, cost-effective, and comprehensive approach to preparedness for and response to international public health emergencies. In addition, the committee calls for continued investments at the national level—and increased investments at the international level—to improve capabilities to confront the growing and alarming threat of antimicrobial resistance. • Maintain a sustained response to the continuous threats of communicable diseases: Dedicated efforts of national governments, foundations, and the global community have resulted in millions of lives saved from AIDS, tuberculosis (TB), and malaria, yet all three diseases continue to pose immediate and longer-term threats to the health of populations around the world. More than 36 million people are living with HIV, with 2 million new infections occurring each year. TB disproportionately affects the poorest populations of the world, killing 1.4 million each year, while dangerous resistant strains are becoming more prevalent and easily spread. The mortality rate due to malaria has decreased by more than 60 percent in the last 10 years, but those infected can lose 25 percent of their family's income as a result of their lost productivity, affecting the prosperity of the society at large as well. The committee believes that a sustained focus on HIV/AIDS and malaria and a reevaluation of the commitment to fghting TB are imperative to prevent reversal of the gains achieved in the last few decades and avoid the further spread of resistant strains for all three diseases. The committee also identifed three areas for action to maximize the returns on investments, achieve better health outcomes, and use funding more effectively: • Catalyze innovation through both the accelerated development of medical products and integrated digital health infrastructure; • Employ more nimble and fexible fnancing mechanisms to leverage new partners and funders in global health • Maintain U.S. status and infuence as a world leader in global health while adhering to evidence-based science and economics, measurement, and accountability As the committee noted, "Achieving true improvements in global health will require changing the way global health business is conducted to better enable innovation. Adequately protecting U.S. citizens at home and abroad necessitates not only investment in U.S. infrastructure, but also continued awareness of global issues and active engagement in the international global health arena ... To these ends, a change in approach and long-term visioning across the various U.S. agencies involved in global health will be necessary, with an emphasis on integration and partnership." Federal entities in the U.S. have responded to the call for action. For example, last year, the Department of Health and Human Services (HHS) updated its Pandemic Infuenza Plan, highlighting both the progress and remaining gaps in preparedness and response capabilities for pandemic infuenza. It outlined seven domains for 2017-2027: 1. Surveillance, Epidemiology, and Laboratory Activities: Better detection and monitoring of seasonal and emerging novel infuenza viruses are critical to assuring a rapid recognition and response to a pandemic. Over the next decade, HHS will increase use of new gene sequencing technologies for detecting and characterizing infuenza viruses in the U.S. and globally. Candidate vaccine viruses will be more rapidly developed and synthesized when needed, to speed manufacturing of vaccines. Greater use of 'big data', analytics, and forecasting will enhance surveillance and planning. 2.Community Mitigation Measures: Incorporating actions and response measures that people and communities can take to help slow the spread of novel infuenza virus. Community mitigation

Articles in this issue

Links on this page

Archives of this issue

view archives of Infection Control Today - OCT 2018